Sunshine Biopharma, Inc. SBFM
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 35.35M | 35.49M | 36.31M | 37.32M | 36.34M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 35.35M | 35.49M | 36.31M | 37.32M | 36.34M |
| Cost of Revenue | 24.64M | 23.79M | 24.05M | 25.00M | 24.23M |
| Gross Profit | 10.71M | 11.71M | 12.26M | 12.32M | 12.11M |
| SG&A Expenses | 14.81M | 15.03M | 15.33M | 15.75M | 16.20M |
| Depreciation & Amortization | 349.60K | 344.10K | 332.00K | 298.50K | 267.30K |
| Other Operating Expenses | 514.60K | 488.80K | 469.30K | 451.60K | 388.20K |
| Total Operating Expenses | 40.55M | 40.07M | 40.78M | 42.18M | 41.77M |
| Operating Income | -5.20M | -4.58M | -4.48M | -4.86M | -5.43M |
| Income Before Tax | -5.56M | -5.98M | -5.95M | -6.51M | -6.47M |
| Income Tax Expenses | 271.00K | 61.80K | 21.60K | -515.50K | -162.90K |
| Earnings from Continuing Operations | -5.83 | -6.04 | -5.98 | -5.99 | -6.31 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -5.83M | -6.04M | -5.98M | -5.99M | -6.31M |
| EBIT | -5.20M | -4.58M | -4.48M | -4.86M | -5.43M |
| EBITDA | -4.85M | -4.23M | -4.15M | -4.56M | -5.17M |
| EPS Basic | -200.66 | -256.52 | -293.10 | -405.49 | -366.69 |
| Normalized Basic EPS | -99.77 | -110.98 | -135.70 | -227.33 | -214.81 |
| EPS Diluted | -200.66 | -256.52 | -293.10 | -405.49 | -366.69 |
| Normalized Diluted EPS | -99.77 | -110.98 | -135.70 | -227.33 | -214.81 |
| Average Basic Shares Outstanding | 139.90K | 94.10K | 83.10K | 69.60K | 46.80K |
| Average Diluted Shares Outstanding | 139.90K | 94.10K | 83.10K | 69.60K | 46.80K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |